AN2 Therapeutics, Inc.

ANTX

Held by 3 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

3 funds opened new positions. Short interest: 7.0% of float.

Share

BiotechnologyCEO: Eric E. EasomIPO: 2022Website ↗

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Signal Score

4.5/10

3 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 3 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

3 fund convergence

Commodore CapitalHeld 2Q ↑

BVF Partners

RA Capital Management

Position history (shares)

Commodore Capital

2Q

AI Signal

BVF Partners exits ANTX. Mark Lampert's fund, known for concentrated, high-conviction biotech value positions, has fully exited AN2 Therapeutics — a notable negative signal for a company developing novel antibiotics (epetraborole) targeting difficult-to-treat NTM lung disease. Despite BVF's exit, three specialist funds remain holders, with RA Capital and Commodore Capital maintaining positions — their continued conviction partially offsets the BVF departure but warrants close monitoring of upcoming clinical or financing catalysts to determine whether Lampert's exit reflects program-specific concerns or portfolio reallocation.

Unlock full AI analysis — 14-day free trial

3 quarters

Position Trend

Nov 14, 2025

$0

0 funds

Feb 17, 2026

$0

0 funds

May 15, 2026

$8.0M

1 fund

Aug 14, 2026

$14.2M

1 fund

-73% total institutional value over 16 quarters

Short Interest

High short interestSI rising 5 periods (+191.2%)

Short Shares

2.22M

Change

-8.7%

Days to Cover

11.4

% of Float

7.0%

Settlement

Aug 14, 2026

Short interest over 12 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GCommodore Capital9.9%Mar 16, 2026

SC 13G/ARA Capital Management0.0%Feb 14, 2025

SC 13G/ARA Capital Management6.7%Aug 13, 2024

SC 13G/ARA Capital Management18.7%Feb 14, 2024

SC 13G/ARA Capital Management19.5%Feb 14, 2023

SC 13GRA Capital Management19.6%Apr 8, 2022

Position Details

Commodore CapitalINCREASEDAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

29 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

AVTX3 funds FDMT2 funds ETNB2 funds AXSM2 funds ELDN2 funds GHRS2 funds IDYA2 funds ITOS2 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer